+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Targeted Therapeutics Market 2021-2026

  • PDF Icon

    Report

  • 156 Pages
  • October 2021
  • Region: Global
  • BCC Research
  • ID: 5456048

The global market for targeted therapeutics should grow from $100.9 billion in 2021 to $142.6 billion by 2026, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2021-2026.




The global market for small molecules should grow from $60.3 billion in 2021 to $83.1 billion by 2026, at a CAGR of 6.6% during the forecast period of 2021-2026.


The global market for monoclonal antibodies should grow from $40.6 billion in 2021 to $59.5 billion by 2026, at a CAGR of 8.0% during the forecast period of 2021-2026.


Report Scope

The scope of this study entails the worldwide market for targeted therapeutics. The report covers the entire market for targeted therapeutics, which incorporates two main types, small molecules and monoclonal antibodies. Based on application, targeted therapeutics is divided into lung cancer, breast cancer, blood cancer, colorectal cancer and others.


By geography, the market has been divided into four regions: North America, Europe, Asia-Pacific and the Rest of the World. Detailed analyses of major countries: the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered. For market estimates, data has been provided for the year 2020 as the base year, with forecasts for 2021-2026. Estimated values are based on drug manufacturer total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.


The Report Includes

  • 24 data tables and 29 additional tables
  • An overview of the global market for targeted therapeutics within the biopharmaceuticals sector
  • Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
  • Evaluation of current market size and market forecast for targeted therapeutics, technological advancements, and corresponding market share analysis by type, application and geographic region
  • A detailed description of the target-specific functionality, advantages of target therapeutics, their production and processes, and discussion on their ability to provide therapeutic treatments for various chronic diseases
  • Coverage of disease and economic burden of cancer, types of cancer therapy and insights into cancer treatment strategy timeline
  • Insight into global R&D activities related to oncology drugs, industry structure, product launches, clinical trials, and regulatory scenarios affecting the future marketplace
  • Competitive landscape and pipeline analysis of the key companies operating in the global market, their company share analysis, and relevant oncology drug licensing deals and M&A deals
  • Company profiles of major industry players, including Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), F. Hoffmann-La Roche Ltd., Pfizer, Novartis, Merck & Co., and Takeda Pharmaceutical Co., Ltd.
Frequently Asked Questions about the Global Targeted Therapeutics Market

What is the estimated value of the Global Targeted Therapeutics Market?

The Global Targeted Therapeutics Market was estimated to be valued at $100.9 Billion in 2021.

What is the growth rate of the Global Targeted Therapeutics Market?

The growth rate of the Global Targeted Therapeutics Market is 7.2%, with an estimated value of $142.6 Billion by 2026.

What is the forecasted size of the Global Targeted Therapeutics Market?

The Global Targeted Therapeutics Market is estimated to be worth $142.6 Billion by 2026.

Who are the key companies in the Global Targeted Therapeutics Market?

Key companies in the Global Targeted Therapeutics Market include Amgen Inc., Astrazeneca, Bayer Ag, Boehringer Ingelheim International Gmbh, Bristol, Myers Squibb, F. Hoffmann, La Roche Ltd. and Novartis Ag.

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Intended Audience
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports


Chapter 2 Summary and Highlights
  • Market Size and Evolution


Chapter 3 Market Overview
  • Cancer Burden
  • Causes of Cancer
  • Genetic Factors
  • Lifestyle Factors
  • Environmental Factors
  • Cancer-Causing Genes
  • Immune System and Cancer
  • Cancer Prevention
  • Types of Cancer Treatment
  • Non-pharmacological Approaches
  • Pharmacological Approaches
  • Gene Therapy
  • Market Dynamics
  • Drivers
  • Restraints
  • Opportunity


Chapter 4 Impact of COVID-19 on Market
  • Overview
  • Current Outlook
  • Impact of COVID-19 on Cancer Care


Chapter 5 Regulatory Aspects
  • Overview
  • United States
  • New Drug Application (NDA)
  • Fast-Track Status
  • Europe
  • Japan
  • India
  • New Drug Approval
  • Import Registration Certificate
  • Import License
  • China


Chapter 6 Market Breakdown by Type of Targeted Therapy
  • Overview
  • Small Molecules
  • Market Size and Forecast
  • Market Analysis
  • Monoclonal Antibodies
  • Market Size and Forecast
  • Market Analysis


Chapter 7 Market Breakdown by Application
  • Overview
  • Lung Cancer
  • Market Size and Forecast
  • Market Analysis
  • Breast Cancer
  • Market Size and Forecast
  • Market Analysis
  • Blood Cancer
  • Market Size and Forecast
  • Market Analysis
  • Colorectal Cancer
  • Market Size and Forecast
  • Market Analysis
  • Other Cancers
  • Market Size and Forecast
  • Market Analysis


Chapter 8 Market Breakdown by Region
  • Introduction
  • North America
  • Market Analysis
  • U.S.
  • Canada
  • Europe
  • Market Impact
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Market Analysis
  • China
  • India
  • Japan
  • Rest of Asia-Pacific
  • Rest of the World
  • Market Size and Forecast


Chapter 9 Industry Structure
  • Company Landscape
  • Pipeline Analysis
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV Clinical Trials


Chapter 10 Company Profiles
  • Amgen Inc.
  • Astrazeneca
  • Bayer Ag
  • Boehringer Ingelheim International Gmbh
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis Ag
  • Pfizer
  • Takeda Pharmaceutical Co., Ltd.


Chapter 11 Appendix: Acronyms
List of Tables
Summary Table: Global Market for Targeted Therapeutics, by Type, Through 2026
Table 1: Cancer Treatment Types
Table 2: Cancer Treatment Strategy Timeline
Table 3: List of Cancer Drug/Imaging Agent Approvals, 2020
Table 4: Patent Expiration Dates, Targeted Therapy Drugs
Table 5: Side Effects of Targeted Therapies
Table 6: Coronavirus Reported Cases and Deaths, by Country, 2020
Table 7: FDA Approval Date, Selected Targeted Therapeutic Drugs
Table 8: Global Market for Targeted Therapeutics, by Type, Through 2026
Table 9: Global Market for Cancer Small Molecule Therapy, by Region, Through 2026
Table 10: Selected Small Molecule Inhibitors for Cancer Therapy
Table 11: Global Market for Cancer Monoclonal Antibody Therapy, by Region, Through 2026
Table 12: Selected Approved/Under-Review MAB Cancer Therapeutics in the U.S. and EU
Table 13: Global Market for Targeted Therapeutics, by Application, Through 2026
Table 14: Global Market for Targeted Therapeutics for Lung Cancer, by Region, Through 2026
Table 15: Some Targeted Therapeutics for Lung Cancer
Table 16: Global Market for Targeted Therapeutics for Breast Cancer, by Region, Through 2026
Table 17: Global Market for Targeted Therapeutics for Blood Cancer, by Region, Through 2026
Table 18: Global Market for Targeted Therapeutics for Colorectal Cancer, by Region, Through 2026
Table 19: Global Market for Targeted Therapeutics for Other Types of Cancer, by Region, Through 2026
Table 20: Global Market for Targeted Therapeutics, by Region, Through 2026
Table 21: North American Market for Targeted Therapeutics, by Type, Through 2026
Table 22: North American Market for Targeted Therapeutics, by Application, Through 2026
Table 23: North American Market for Targeted Therapeutics, by Country, Through 2026
Table 24: European Market for Targeted Therapeutics, by Type, Through 2026
Table 25: European Market for Targeted Therapeutics, by Application, Through 2026
Table 26: European Market for Targeted Therapeutics, by Country, Through 2026
Table 27: Asia-Pacific Market for Targeted Therapeutics, by Type, Through 2026
Table 28: Asia-Pacific Market for Targeted Therapeutics, by Application, Through 2026
Table 29: Asia-Pacific Market for Targeted Therapeutics, by Country, Through 2026
Table 30: Rest of the World Market for Targeted Therapeutics, by Type, Through 2026
Table 31: Rest of the World Market for Targeted Therapeutics, by Application, Through 2026
Table 32: Revenue: Selected Targeted Therapeutics, 2019 and 2020
Table 33: Oncology Drug Licensing Deals, 2020
Table 34: Oncology Merger and Acquisition Deals, 2020
Table 35: Selected Targeted Therapeutics in Phase I Clinical Trials, 2021
Table 36: Selected Targeted Therapeutics in Phase II Clinical Trials, 2021
Table 37: Selected Targeted Therapeutics in Phase III Clinical Trials, 2021
Table 38: Selected Targeted Therapeutics in Phase IV Clinical Trials, 2021
Table 39: Amgen Inc.: Marketed Products, 2020
Table 40: AstraZeneca: Marketed Products, 2020
Table 41: Bayer AG: Marketed Products, 2020
Table 42: Boehringer Ingelheim International GmbH: Marketed Products, 2020
Table 43: Bristol-Myers Squibb: Marketed Products, 2020
Table 44: Bristol-Myers Squibb: Selected Product Approvals, 2020-2021
Table 45: F. Hoffmann-La Roche Ltd.: Marketed Products, 2020
Table 46: Merck & Co., Inc.: Marketed Products, 2020
Table 47: Merck & Co., Inc.: Selected Product Approvals, 2020
Table 48: Novartis AG: Marketed Products, 2020
Table 49: Pfizer: Marketed Products, 2020
Table 50: Takeda Pharmaceutical Co., Ltd.: Marketed Products, 2020
Table 51: Takeda Pharmaceutical Co., Ltd.: Selected Product Approval, 2020-2021
Table 52: Acronyms Used in This Report


List of Figures
Summary Figure: Global Market Shares of Targeted Therapeutics, by Type, 2020
Figure 1: Global Estimated Cancer Cases, All Ages, by Cancer Type, 2020
Figure 2: Global Estimated Cancer Cases, All Ages, 2020
Figure 3: Global Estimated Cancer Related Deaths, All Ages, 2020
Figure 4: Distribution of New Cancer Cases in Women, 2020
Figure 5: Distribution of New Cancer Cases in Men, 2020
Figure 6: Global Estimated New Cancer Cases, by Region, 2020 vs. 2040
Figure 7: National Cancer Institute Research Funding, 2012-2019
Figure 8: Global Market Shares of Targeted Therapeutics, by Type, 2020
Figure 9: Global Market for Cancer Small Molecule Therapy, 2019-2026
Figure 10: Global Market for Cancer Small Molecule Therapy, by Region, 2019-2026
Figure 11: Global Market for Cancer Monoclonal Antibody Therapy, 2019-2026
Figure 12: Global Market for Cancer Monoclonal Antibody Therapy, by Region, 2019-2026
Figure 13: Approved Antibody Therapeutics in the U.S. and EU, 2010-2020
Figure 14: Global Market Shares of Targeted Therapeutics, by Application, 2020
Figure 15: Global Market for Targeted Therapeutics for Lung Cancer, 2019-2026
Figure 16: Global Market for Targeted Therapeutics for Lung Cancer, by Region, 2019-2026
Figure 17: Prevalence of Lung Cancer Cases, by Continent, 2015-2020
Figure 18: Global Market for Targeted Therapeutics for Breast Cancer, 2019-2026
Figure 19: Global Market for Targeted Therapeutics for Breast Cancer, by Region, 2019-2026
Figure 20: Prevalence of Breast Cancer Cases, by Continent, 2015-2020
Figure 21: Global Market for Targeted Therapeutics for Blood Cancer, 2019-2026
Figure 22: Global Market for Targeted Therapeutics for Blood Cancer, by Region, 2019-2026
Figure 23: Share of New Blood Cancer Cases in the U.S., by Cancer Type, 2021
Figure 24: Global Market for Targeted Therapeutics for Colorectal Cancer, 2019-2026
Figure 25: Global Market for Targeted Therapeutics for Colorectal Cancer, by Region, 2019-2026
Figure 26: Prevalence of Colorectal Cancer Cases, by Continent, 2015-2020
Figure 27: Global Market for Targeted Therapeutics for Other Types of Cancer, 2019-2026
Figure 28: Global Market for Targeted Therapeutics for Other Types of Cancer, by Region, 2019-2026
Figure 29: Global Market for Targeted Therapeutics, by Region, 2019-2026
Figure 30: North American Market Shares of Targeted Therapeutics, by Type, 2020
Figure 31: North American Market Shares of Targeted Therapeutics, by Application, 2020
Figure 32: North American Market Shares of Targeted Therapeutics, by Country, 2020
Figure 33: U.S. Market for Targeted Therapeutics, 2019-2026
Figure 34: Canadian Market for Targeted Therapeutics, 2019-2026
Figure 35: European Market Shares of Targeted Therapeutics, by Type, 2020
Figure 36: European Market Shares of Targeted Therapeutics, by Application, 2020
Figure 37: European Market Shares of Targeted Therapeutics, by Country, 2020
Figure 38: German Market for Targeted Therapeutics, 2019-2026
Figure 39: U.K. Market for Targeted Therapeutics, 2019-2026
Figure 40: French Market for Targeted Therapeutics, 2019-2026
Figure 41: Italian Market for Targeted Therapeutics, 2019-2026
Figure 42: Spanish Market for Targeted Therapeutics, 2019-2026
Figure 43: Rest of European Market for Targeted Therapeutics, 2019-2026
Figure 44: Asia-Pacific Market Shares of Targeted Therapeutics, by Type, 2020
Figure 45: Asia-Pacific Market Shares of Targeted Therapeutics, by Application, 2020
Figure 46: Asia-Pacific Market Shares of Targeted Therapeutics, by Country, 2020
Figure 47: Chinese Market for Targeted Therapeutics, 2019-2026
Figure 48: Indian Market for Targeted Therapeutics, 2019-2026
Figure 49: Japanese Market for Targeted Therapeutics, 2019-2026
Figure 50: Rest of Asia-Pacific Market for Targeted Therapeutics, 2020-2026
Figure 51: Rest of the World Market Shares of Targeted Therapeutics, by Type, 2020
Figure 52: Rest of the World Market Shares of Targeted Therapeutics, by Application, 2020
Figure 53: Company Share Analysis of the Global Targeted Therapeutics Market, 2020
Figure 54: Distribution of Clinical Trials on Targeted Therapeutics, by Phase, 2021
Figure 55: Amgen Inc.: Annual Revenue, 2018-2020
Figure 56: Amgen Inc.: Revenue Share, by Product Sales, 2020
Figure 57: Amgen Inc.: Revenue Share, by Geography, 2020
Figure 58: AstraZeneca: Annual Revenue, 2018-2020
Figure 59: AstraZeneca: Oncology Segment Revenue, 2018-2020
Figure 60: AstraZeneca: Revenue Share, by Geography, 2020
Figure 61: Bayer AG: Annual Revenue, 2018-2020
Figure 62: Bayer AG: Revenue Share, by Segment, 2020
Figure 63: Bayer AG: Revenue Share, by Geography, 2020
Figure 64: Boehringer Ingelheim International GmbH: Annual Revenue, 2018-2020
Figure 65: Boehringer Ingelheim International GmbH: Revenue Share, by Segment, 2020
Figure 66: Boehringer Ingelheim International GmbH: Revenue Share, by Geography, 2020
Figure 67: Bristol-Myers Squibb: Annual Revenue, 2018-2020
Figure 68: Bristol-Myers Squibb: Revenue Share, by Geography, 2020
Figure 69: F. Hoffmann-La Roche Ltd.: Annual Revenue, 2018-2020
Figure 70: F. Hoffmann-La Roche Ltd.: Revenue Share, by Segment, 2020
Figure 71: F. Hoffmann-La Roche Ltd.: Revenue Share, by Geography, 2020
Figure 72: Merck & Co., Inc.: Annual Revenue, 2018-2020
Figure 73: Merck & Co., Inc.: Revenue Share, by Segment, 202
Figure 74: Merck & Co., Inc.: Revenue Share, by Geography, 2020
Figure 75: Novartis AG: Financial Performance, 2018-2020
Figure 76: Novartis AG: Revenue Share, by Segment, 2020
Figure 77: Novartis AG: Revenue Share, by Geography, 2020
Figure 78: Pfizer: Annual Revenue, 2018-2020
Figure 79: Pfizer: Oncology Segment Revenue, 2018-2020
Figure 80: Pfizer: Revenue Share, by Geography, 2020
Figure 81: Takeda Pharmaceutical Co., Ltd.: Annual Revenue, 2018-2020
Figure 82: Takeda Pharmaceutical Co., Ltd.: Revenue Share, by Segment, 2020
Figure 83: Takeda Pharmaceutical Co., Ltd.: Revenue Share, by Geography, 2020

Samples

Loading
LOADING...

Executive Summary

Cancer was the leading cause of death in 2020, accounting for 10 million deaths, globally. This disease includes multi-gene mutations that produce altered proteins controlling the signalling pathway of cells. Usually, proteins encoded by these genes control cell growth, apoptosis, DNA repair, division and checkpoint, creating cancerous cells. But changes in these genes produce altered proteins that enable cancer.


Targeted therapeutics is an emerging and promising approach for oncology treatment, targeting the proteins that stimulate the growth of cancer cells. Small molecules offer more advantages than monoclonal antibodies, targeting molecules inside the cells (along with surface receptors) to modulate protein function. The dynamic field of cancer R&D offers specialization in targeted therapies, which play a crucial role as mediators in cancer and other diseases, modulating diverse cellular activities.


The market for targeted therapeutics has an increasing demand. As the field of targeted therapy matures, market leaders must use technologies and methods for novel targets and therapeutic approaches.


Market Size and Evolution


Emerging markets, particularly in the Asia-Pacific region, have shown growth potential in recent years. Rising affluence in these countries brings a change in lifestyles, resulting in an increased incidence of cancer. Developing countries in Africa and elsewhere are still battling some of the highest proportions of immune-mediated diseases. The need for affordable and innovative medicines drives growth in the targeted therapeutics market in the low- and middle-income developing countries.


Companies Mentioned

  • Amgen Inc.
  • Astrazeneca
  • Bayer Ag
  • Boehringer Ingelheim International Gmbh
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis Ag
  • Pfizer
  • Takeda Pharmaceutical Co., Ltd.